A 24 Weeks, Multi-centers, Single Arm Phase IV Study to Evaluate the Safety of "Shinbaro Capsule" Compared With Historical Data of "Celebrex Capsule" in Patients With Osteoarthritis
Phase of Trial: Phase IV
Latest Information Update: 02 Jan 2018
At a glance
- Drugs GCSB 5 (Primary) ; Celecoxib
- Indications Osteoarthritis
- Focus Adverse reactions
- Sponsors GC Pharma; Green Cross
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
- 29 Apr 2013 Planned End Date changed from 1 Mar 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 29 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.